UY33491A - ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. - Google Patents
?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.Info
- Publication number
- UY33491A UY33491A UY0001033491A UY33491A UY33491A UY 33491 A UY33491 A UY 33491A UY 0001033491 A UY0001033491 A UY 0001033491A UY 33491 A UY33491 A UY 33491A UY 33491 A UY33491 A UY 33491A
- Authority
- UY
- Uruguay
- Prior art keywords
- medicine
- pharmaceutically acceptable
- sulfonamide derivatives
- acceptable salts
- inhibitors
- Prior art date
Links
- 229940124530 sulfonamide Drugs 0.000 title abstract 3
- 150000003456 sulfonamides Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 229940124777 Nav1.7 inhibitor Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36292710P | 2010-07-09 | 2010-07-09 | |
| US201161492525P | 2011-06-02 | 2011-06-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY33491A true UY33491A (es) | 2012-02-29 |
Family
ID=45439019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001033491A UY33491A (es) | 2010-07-09 | 2011-07-07 | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8772293B2 (enExample) |
| EP (1) | EP2590951B1 (enExample) |
| JP (1) | JP5830534B2 (enExample) |
| AR (1) | AR082201A1 (enExample) |
| CA (1) | CA2804593C (enExample) |
| ES (1) | ES2533065T3 (enExample) |
| UY (1) | UY33491A (enExample) |
| WO (1) | WO2012004743A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2532356T3 (es) | 2010-07-09 | 2015-03-26 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
| US9096558B2 (en) | 2010-07-09 | 2015-08-04 | Pfizer Limited | N-sulfonylbenzamide compounds |
| WO2012007868A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
| CA2804877A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
| ES2525581T3 (es) | 2010-07-12 | 2014-12-26 | Pfizer Limited | Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje |
| CA2804351A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| WO2013064983A1 (en) * | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| EP2773641B1 (en) | 2011-10-31 | 2017-09-27 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| WO2013137371A1 (ja) * | 2012-03-15 | 2013-09-19 | 興和株式会社 | 新規ピリミジン化合物及びそれらを含有する医薬 |
| WO2013161928A1 (ja) * | 2012-04-26 | 2013-10-31 | 塩野義製薬株式会社 | オキサゾロトリアゾール誘導体およびそれらを含有する医薬組成物 |
| SG11201408284VA (en) | 2012-05-22 | 2015-02-27 | Xenon Pharmaceuticals Inc | N-substituted benzamides and their use in the treatment of pain |
| US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| EP2906558B1 (en) * | 2012-10-15 | 2020-09-02 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
| BR112015008987A2 (pt) | 2012-10-26 | 2017-07-04 | Merck Sharp & Dohme | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| US9493429B2 (en) | 2013-03-15 | 2016-11-15 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| CA2900604A1 (en) * | 2013-03-15 | 2014-09-25 | Chromocell Corporation | Sodium channel modulators for the treatment of pain |
| TW201443025A (zh) * | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| AU2014318979B2 (en) | 2013-09-10 | 2019-03-28 | Chromocell Corporation | Sodium channel modulators for the treatment of pain and diabetes |
| AU2014356967A1 (en) | 2013-11-27 | 2016-07-07 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| US10468036B2 (en) * | 2014-04-30 | 2019-11-05 | Accusonus, Inc. | Methods and systems for processing and mixing signals using signal decomposition |
| CA2950393A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Benzenesulfonamides useful as sodium channel inhibitors |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| WO2016034971A1 (en) | 2014-09-04 | 2016-03-10 | Pfizer Limited | Sulfonamides derivatives as urat1 inhibitors |
| BR112017024853A2 (pt) | 2015-05-22 | 2018-08-07 | Genentech Inc | composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto |
| MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
| SG10202007787RA (en) | 2015-09-28 | 2020-09-29 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| KR20180080187A (ko) * | 2015-11-06 | 2018-07-11 | 다이이찌 산쿄 가부시키가이샤 | 디메톡시벤질기의 탈리 방법 |
| JP2018535234A (ja) | 2015-11-25 | 2018-11-29 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル遮断薬として有用な置換ベンズアミド |
| BR112018012327A2 (pt) | 2015-12-18 | 2018-12-04 | Merck Sharp & Dohme | compostos de diamina-arilsulfonamida substituídos com hidroxialquilamina e hidroxicicloalquilamina com atividade seletiva em canais de sódio ativados por voltagem |
| WO2017172802A1 (en) | 2016-03-30 | 2017-10-05 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| ES3022639T3 (en) | 2016-05-20 | 2025-05-28 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
| SG11201903348UA (en) | 2016-10-17 | 2019-05-30 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| CN110325531B (zh) | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
| EP3759098A1 (en) | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
| CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| BR112020024729A2 (pt) | 2018-06-13 | 2021-03-23 | Xenon Pharmaceuticals, Inc. | compostos de benzenossulfonamida e seu uso como agentes terapêuticos |
| IL279810B2 (en) | 2018-08-31 | 2025-03-01 | Xenon Pharmaceuticals Inc | Heteroaryl-modified sulfonamide compounds and their use as medicinal agents |
| MA53488A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| EP3891157A4 (en) | 2018-12-05 | 2022-08-31 | Merck Sharp & Dohme Corp. | 4-AMINO- OR 4-ALKOXY-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATE SODIUM CHANNELS |
| TW202216671A (zh) * | 2020-06-25 | 2022-05-01 | 瑞士商諾華公司 | １，４—二取代的嗒𠯤化合物之製造方法 |
| MX2024007858A (es) * | 2021-12-23 | 2024-09-04 | Veralox Therapeutics | Composiciones y metodos de uso para tratar enfermedades mediadas por 12-lipoxigenasa (12-lox). |
| WO2025160284A1 (en) * | 2024-01-23 | 2025-07-31 | The Board Of Trustees Of The University Of Illinois | Algorithm for computer-assisted molecular modularization |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR71915B (enExample) | 1979-11-27 | 1983-08-16 | Pfizer | |
| EP0194599A3 (en) | 1985-03-14 | 1988-01-20 | Nissan Chemical Industries Ltd. | Benzamide derivatives, process for producing the same, and soil fungicides containing the same |
| BR8707779A (pt) | 1986-08-20 | 1989-08-15 | Fmc Corp | Herbicidas |
| US5084085A (en) | 1986-08-20 | 1992-01-28 | Fmc Corporation | Herbicidal aryloxyphenyltriazolinones and related compounds |
| US4845264A (en) | 1987-03-05 | 1989-07-04 | Teijin Limited | Phenoxycarboxylic acid and herbicide comprising it as active ingredient |
| US4920132A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4920130A (en) | 1987-11-02 | 1990-04-24 | Rorer Pharamceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4920133A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4920131A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| EP0325245B1 (en) | 1988-01-19 | 1993-10-20 | Tanabe Seiyaku Co., Ltd. | Phenoxyacetic acid derivatives, preparation thereof, pharmaceutical compositions comprising them and use |
| GB8911854D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
| IE902909A1 (en) | 1989-08-11 | 1991-02-27 | Ici Plc | Nitrogen compounds |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| EP0453210A3 (en) | 1990-04-19 | 1993-01-13 | Imperial Chemical Industries Plc | Pyridine derivatives |
| WO1993000332A1 (en) | 1991-06-25 | 1993-01-07 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| GB2266527A (en) | 1992-03-17 | 1993-11-03 | Merck & Co Inc | Substituted azetidinones useful in the treatment of leukemia |
| JPH05289262A (ja) | 1992-04-10 | 1993-11-05 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| JPH05307242A (ja) | 1992-04-28 | 1993-11-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| JP3101848B2 (ja) | 1992-05-15 | 2000-10-23 | 富士写真フイルム株式会社 | ハロゲン化銀カラー写真感光材料 |
| FR2694295B1 (fr) | 1992-07-28 | 1994-09-02 | Adir | Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent. |
| AU5802894A (en) | 1992-12-17 | 1994-07-04 | Merck & Co., Inc. | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
| ES2141197T3 (es) | 1993-03-19 | 2000-03-16 | Merck & Co Inc | Derivados del acido fenoxifenilacetico. |
| JPH06347968A (ja) | 1993-04-14 | 1994-12-22 | Fuji Photo Film Co Ltd | ハロゲン化銀感光材料 |
| DK77393D0 (da) | 1993-06-29 | 1993-06-29 | Novo Nordisk As | Aktivering af enzymer |
| JP3503839B2 (ja) | 1994-05-25 | 2004-03-08 | 富士写真フイルム株式会社 | ポジ型感光性組成物 |
| CA2195758A1 (en) | 1994-08-08 | 1996-02-22 | Scott W. Bagley | Phenoxyphenylacetic acid derivatives |
| WO1996009818A1 (en) | 1994-09-27 | 1996-04-04 | Merck & Co., Inc. | Endothelin receptor antagonists for the treatment of emesis |
| US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
| GB9514031D0 (en) | 1995-07-10 | 1995-09-06 | Zeneca Ltd | Chemical process |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| JP3519218B2 (ja) | 1996-08-14 | 2004-04-12 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料および画像形成方法 |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| WO1999000372A1 (fr) | 1997-06-27 | 1999-01-07 | Fujisawa Pharmaceutical Co., Ltd. | Sulfamides et leur utilisation medicale |
| US6555584B1 (en) | 2000-06-29 | 2003-04-29 | Ajinomoto Co., Inc. | Acylsulfonamide derivative |
| DE19742951A1 (de) | 1997-09-29 | 1999-04-15 | Hoechst Schering Agrevo Gmbh | Acylsulfamoylbenzoesäureamide, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung |
| HUP0101022A1 (hu) | 1997-10-17 | 2001-10-28 | Aventis Pharmaceuticals Products Inc. | Kinolinszármazékok gyógyászati alkalmazása |
| CA2300197A1 (en) | 1997-12-23 | 1999-07-01 | Warner-Lambert Company | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
| GB9805520D0 (en) | 1998-03-17 | 1998-05-13 | Zeneca Ltd | Chemical compounds |
| GT199900044A (es) | 1998-04-10 | 2000-09-14 | Procedimientos para preparar haluros de fenoxifenilsulfonilo. | |
| DE19851184A1 (de) | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-Arylsulfonyl-aminosäure-omega-amide |
| GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
| WO2000064876A1 (en) | 1999-04-28 | 2000-11-02 | Aventis Pharma Deutschland Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
| JP2002543130A (ja) | 1999-05-05 | 2002-12-17 | メルク エンド カムパニー インコーポレーテッド | 抗微生物剤としての新規なカテコール類 |
| JP2003500376A (ja) | 1999-05-24 | 2003-01-07 | シーオーアール セラピューティクス インコーポレイテッド | Ｘａ因子の阻害剤 |
| CA2374820A1 (en) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
| JP2003500386A (ja) | 1999-05-24 | 2003-01-07 | シーオーアール セラピューティクス インコーポレイテッド | Ｘａ因子阻害剤 |
| JP2001075213A (ja) | 1999-09-07 | 2001-03-23 | Fuji Photo Film Co Ltd | ハロゲン化銀写真乳剤、その製造方法及びこれを用いたハロゲン化銀写真感光材料 |
| JP2003510304A (ja) | 1999-09-29 | 2003-03-18 | ノボ ノルディスク アクティーゼルスカブ | 新規芳香族化合物 |
| WO2001027068A1 (en) | 1999-10-13 | 2001-04-19 | Pfizer Products Inc. | Biaryl ether derivatives useful as monoamine reuptake inhibitors |
| GB9927056D0 (en) | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| JP2004500389A (ja) | 2000-03-09 | 2004-01-08 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｐｐａｒメディエーターの治療での使用 |
| UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| EP1260221A3 (en) | 2001-05-23 | 2002-12-18 | Pfizer Products Inc. | Combination treatment for depression and anxiety |
| SE0101978D0 (sv) | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | New compounds |
| MXPA04004654A (es) | 2001-11-16 | 2005-05-17 | Toyama Chemical Co Ltd | Novedosos derivados de benzofenona o sus sales. |
| US20050288346A1 (en) | 2002-08-26 | 2005-12-29 | Cube Rowena V | Acetophenone potentiators of metabotropic glutamate receptors |
| JP2006507359A (ja) | 2002-10-28 | 2006-03-02 | ノボ・ノルデイスク・エー／エス | 心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用 |
| CA2516078C (en) | 2003-02-28 | 2014-04-29 | Oxigene, Inc. | Catechol compositions and use thereof |
| KR20060073930A (ko) | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| NZ548208A (en) | 2004-02-12 | 2010-09-30 | Transtech Pharma Inc | Substituted azole derivatives, compositions, and methods of use |
| GB0405033D0 (en) | 2004-03-05 | 2004-04-07 | Karobio Ab | Novel pharmaceutical compositions |
| MXPA06012613A (es) | 2004-05-07 | 2007-01-31 | Amgen Inc | Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer. |
| EP1773792A1 (en) | 2004-07-30 | 2007-04-18 | Merck & Co., Inc. | Indanone potentiators of metabotropic glutamate receptors |
| MX2007004781A (es) | 2004-10-20 | 2007-05-11 | Applied Research Systems | Derivados de 3-arilamino piridina. |
| JP2008189549A (ja) | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
| EP1963259B1 (en) | 2005-12-15 | 2012-02-15 | AstraZeneca AB | Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease |
| JP2009057282A (ja) | 2005-12-19 | 2009-03-19 | Astellas Pharma Inc | カルボン酸誘導体又はその塩 |
| CA2652307A1 (en) | 2006-04-10 | 2007-10-18 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| SI2076508T1 (sl) | 2006-10-18 | 2011-04-29 | Pfizer Prod Inc | Spojine biaril eter sečnine |
| MX2009008099A (es) | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. |
| JP5361857B2 (ja) | 2007-03-23 | 2013-12-04 | ファイザー・リミテッド | イオンチャネルの阻害剤 |
| WO2008135826A2 (en) | 2007-05-03 | 2008-11-13 | Pfizer Limited | 2 -pyridine carboxamide derivatives as sodium channel modulators |
| TW200911245A (en) | 2007-06-07 | 2009-03-16 | Astellas Pharma Inc | Pyridone derivatives |
| WO2009012242A2 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| RU2010118481A (ru) | 2007-10-11 | 2011-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Амиды, применимые в качестве ингибиторов потенциалзависимых натриевых каналов |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| TW200930368A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| WO2009067541A2 (en) | 2007-11-20 | 2009-05-28 | Gilead Sciences, Inc. | Integrase inhibitors |
| AU2008326309C1 (en) | 2007-11-21 | 2015-03-12 | Decode Genetics Ehf | Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders |
| GB0725214D0 (en) | 2007-12-24 | 2008-02-06 | Karobio Ab | Pharmaceutical compounds |
| BRPI0907978A2 (pt) | 2008-02-15 | 2015-08-04 | Basf Se | Uso de compostos, composição agroquímica, método para combater fungos nocivos, semente, compostos, e, processo para preparar os mesmos |
| EP2119690A1 (en) | 2008-05-14 | 2009-11-18 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Radiolabelled MMP selective compounds |
| JP2011521924A (ja) | 2008-05-28 | 2011-07-28 | ビーエーエスエフ ソシエタス・ヨーロピア | 殺菌剤としての置換ピリジン−４−イル−メチルスルホンアミド |
| MX2010014232A (es) | 2008-06-23 | 2011-03-25 | Astellas Pharma Inc | Compuesto de sulfamida o sal del mismo. |
| US8107894B2 (en) | 2008-08-12 | 2012-01-31 | Raytheon Company | Modular solid-state millimeter wave (MMW) RF power source |
| EA020460B1 (ru) * | 2009-01-12 | 2014-11-28 | Пфайзер Лимитед | Производные сульфонамида |
| JP5289262B2 (ja) | 2009-09-30 | 2013-09-11 | 京セラドキュメントソリューションズ株式会社 | シート搬送装置とこれを備えた画像読取装置及び画像形成装置 |
| US9096558B2 (en) | 2010-07-09 | 2015-08-04 | Pfizer Limited | N-sulfonylbenzamide compounds |
| ES2532356T3 (es) | 2010-07-09 | 2015-03-26 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
| CA2804877A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
| WO2012007868A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| CA2804351A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
| ES2525581T3 (es) | 2010-07-12 | 2014-12-26 | Pfizer Limited | Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje |
-
2011
- 2011-07-05 ES ES11746620.1T patent/ES2533065T3/es active Active
- 2011-07-05 CA CA2804593A patent/CA2804593C/en not_active Expired - Fee Related
- 2011-07-05 WO PCT/IB2011/052974 patent/WO2012004743A1/en not_active Ceased
- 2011-07-05 EP EP11746620.1A patent/EP2590951B1/en not_active Not-in-force
- 2011-07-05 JP JP2013519189A patent/JP5830534B2/ja not_active Expired - Fee Related
- 2011-07-07 UY UY0001033491A patent/UY33491A/es not_active Application Discontinuation
- 2011-07-08 US US13/178,534 patent/US8772293B2/en not_active Expired - Fee Related
- 2011-07-08 AR ARP110102479A patent/AR082201A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20120010182A1 (en) | 2012-01-12 |
| JP2013531031A (ja) | 2013-08-01 |
| AR082201A1 (es) | 2012-11-21 |
| WO2012004743A1 (en) | 2012-01-12 |
| US8772293B2 (en) | 2014-07-08 |
| CA2804593C (en) | 2015-11-24 |
| EP2590951A1 (en) | 2013-05-15 |
| EP2590951B1 (en) | 2015-01-07 |
| CA2804593A1 (en) | 2012-01-12 |
| JP5830534B2 (ja) | 2015-12-09 |
| ES2533065T3 (es) | 2015-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY33491A (es) | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. | |
| UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| UY33501A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
| NI201200184A (es) | Morfolinopirimidinas y su uso en terapia | |
| ECSP14013324A (es) | Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio | |
| ECSP10010693A (es) | Compuestos pirazólicos 436 | |
| PY1923494A (es) | Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| CU20110145A7 (es) | Derivados de sulfonamida | |
| CL2012001391A1 (es) | Compuestos derivados de triazolopiridina sustituidos, inhibidores de la quinasa mps-1; composición farmacéutica; procedimiento de preparacion; combinación farmacéutica y uso para la profilaxis o tratamiento de una enfermedad hiperproliferativa tal como tumores hematológicos, sólidos y/o sus metástasis; compuestos intermediarios. | |
| ECSP10010178A (es) | Derivados bis-(sulfonilamino) en terapia 066 | |
| DOP2014000133A (es) | Triazolopiridinas sustituidas | |
| UY32156A (es) | Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones. | |
| UY35535A (es) | ?Derivados de fenil sulfonamidas?. | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| CO2021010930A2 (es) | Hidroxipiridoxazepinas como activadores de nrf2 | |
| CR20170468A (es) | Compuestos novedosos | |
| ECSP22083772A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| UY35536A (es) | ?derivados de sulfonamida?. | |
| DOP2021000103A (es) | Pirazoles como moduladores de hemoglobina | |
| ECSP18056196A (es) | Derivados de indano | |
| CU20100250A7 (es) | Compuestos pirazólicos 436 | |
| AR113817A1 (es) | Compuestos útiles para inhibir a cdk7 | |
| CU20100094A7 (es) | Derivados bis-(sulfonilamino) en terapia 066 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20200807 |